Eli Lilly and Company

Pioneer Hi-Bred International, Inc.

Derrick Ryan Witcher

Valentina Pavlovna Gelfanova

Radhakrishnan Rathnachalam

Kristine Kay Kikly

John Edward Hale

Derrick Witcher

James C., III Register

A. Gururaj Rao

John Howard

Terry Euclaire Meyer

Chris Baszycynski

Thomas Czapla

Elizabeth Hood

Ying Tang

Donmienne Doen Mun Leung

Peng Luan

Catherine Brautigam Beidler

Beth Ann Strifler

Barbara Anne Swanson

David Matthew Marquis

Barrett Allan

Radmila Micanovic

Joseph Vincent Manetta

Pia Pauliina Yachi

Alain Philippe Vasserot

Kanwarpal Singh Dhugga

John A Howard

Guihua Lu

David J Peterson

Jirong Lu

George William Singletary

Gan-Yuan Zhong

Wesley B Bruce

Lynne Eileen Sims

Scott E Nichols

Stephen John Demarest

Eric Michael Smith

A Gururaj Rao

Xiufeng Wu

Thomas H Czapla

Andrew L Glasebrook

Gerald W Becker

Court A Saunders

Sheng-Hung Rainbow Tschang

Jeffrey Streetman Boyles

Andrew Charles Vendel

Diana Isabel Ruiz

Timothy Wayne Noblitt

Fredric Jay Cohen

Christy Michelle Newton

Scott Charles Potter

Victor John Wroblewski

Sudhakar Reddy Chintharlapalli

Payal Mehta

Dipak Ratilal Patel

Danise Rogers Subramaniam

Patricia Ann Gonzalez-DeWhitt

Anja Koester

Luhong He

Yuping Anthony Cai

Dennis Patrick Gately

Radhakrishnam Rathnachalamm

Donmienne Doen Leung

Andrew Lawrence Glasebrook

Catherine Brautigam Beilder

Iii Register James C

Provided herein are methods and uses of antibodies against ELR+ CXC chemokines for the treatment of hidradenitis suppurativa. Also provided are doses and dosing regimens for the methods and uses of antibodies against ELR+ CXC chemokines for the treatment of hidradenitis suppurativa.

PAN-ELR+ CXC chemokine antibodies for the treatment of hidradenitis suppurativa

The present invention relates to anti-human CD200R agonist antibodies, and uses thereof for treating diseases such as atopic dermatitis, chronic spontaneous urticaria, allergy, asthma, scleroderma, IBD, SLE, MS, RA, GvHD, or psoriasis.

CD200R agonist antibodies and uses thereof

Antibodies are provided that specifically bind seven human ELR+ CXC chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (IBD), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer.

Pan-ELR+ CXC chemokine antibodies

Bispecific antibodies are provided that bind CD20 and B-cell Activating Factor of the TNF Family (BAFF) and are characterized as having high affinity and strong simultaneous neutralizing properties to both CD20 and BAFF. The bispecific antibodies of the invention are useful for treating autoimmune diseases including Systemic Lupus Erythematosus, Lupus Nephritis, and primary Sj&#xf6;gren's Syndrome.

Anti-CD20&#x2212; / anti-BAFF bispecific antibodies

Antibodies are provided that specifically bind seven human ELRCXC chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (IBD), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer.

[object Object]

Bispecific antibodies are provided that specifically bind both Tumor Necrosis Factor alpha (TNF&#x3b1;) and Interleukin-17 (IL-17). The bispecific antibodies of the invention are useful for treating various autoimmune diseases, including Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), and Ankylosing Spondylitis (AS).

Anti-TNF-anti-IL-17 bispecific antibodies

Pan-ELR+ CXC Chemokine Antibodies

Monoclonal antibodies are provided that selectively bind human hepcidin-25 and are characterized as having high affinity for human hepcidin-25 and strong human mature hepcidin neutralizing properties. The antibodies of the invention are useful therapeutically for increasing serum iron levels, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit in a human and for the treatment and diagnosis of mature hepcidin-promoted disorders such as anemia, in a human subject.

Anti-hepcidin antibodies and uses thereof

Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to, and inhibit the activity of human FPN1, and which are effective in maintaining or increasing the transport of iron out of mammalian cells and/or maintaining or increasing the level of serum iron, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit in a subject in vivo.

Anti-ferroportin 1 monoclonal antibodies and uses thereof

Monoclonal antibodies are provided that bind to the N-terminus of human hepcidin-25 and are characterized as having high affinity and selectivity for the polypeptide. The antibodies of the invention are useful for increasing serum iron levels, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit in a human and for the treatment of various disorders, such as anemia, in a human subject. The antibodies of the invention are also useful as analytical tools, such as in sandwich ELISA.

Anti-hepcidin-25 selective antibodies and uses thereof

Provided are humanized monoclonal antibodies, and antigen-binding portions thereof, which bind acylated and unacylated human ghrelin. Such antibodies are useful for neutralizing ghrelin activity and treating disorders in which ghrelin activity is detrimental, including obesity and related disorders, and various cancers.

Humanized anti-ghrelin antibodies

Growing community of inventors

Fishers, IN, United States of America

Derrick Ryan Witcher